Medicale Corp.

MCLEdata completeness 63%5 fiscal years on file

Data notes: no data for concept 'capex'; no data for concept 'totalDebt'

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$01$01
Net income−$32,1522−$46,4193−$37,1384−$58,2135−$41,1535
Operating cash flow−$17,7526−$24,6197−$25,7398−$83,5859−$23,0089
Capital expenditure
Free cash flow (derived)
Total debt
Cash & equivalents$18,47510$011$15912$15912$012
Diluted shares3.6M5.9M5.9M5.9M5.9M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.24
your share of equity
Profit it earned you last year
−$0.07
Free cash flow it threw off
Debt you’d be carrying

10 shares is a claim on −$0.24 of net worth that earned you −$0.07 last year.

iii. Is this a good business?
Moat signal · return on equity
avg · 5y

Not enough data in the filings for a return-on-capital reading.

seeing a moat in the numbers →
Management signal · capital allocation
+64% shares · 5y

Share count is up 64% over 5 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-09-30 · accession 0001683168-22-008165 (Revenues)
  2. 10-K · period ending 2021-09-30 · accession 0001683168-22-008165 (NetIncomeLoss)
  3. 10-K · period ending 2022-09-30 · accession 0001683168-24-000004 (NetIncomeLoss)
  4. 10-K · period ending 2023-09-30 · accession 0001683168-25-000327 (NetIncomeLoss)
  5. 10-K · period ending 2024-09-30 · accession 0001683168-26-000203 (NetIncomeLoss)
  6. 10-K · period ending 2021-09-30 · accession 0001683168-22-008165 (NetCashProvidedByUsedInOperatingActivities)
  7. 10-K · period ending 2022-09-30 · accession 0001683168-24-000004 (NetCashProvidedByUsedInOperatingActivities)
  8. 10-K · period ending 2023-09-30 · accession 0001683168-25-000327 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K · period ending 2024-09-30 · accession 0001683168-26-000203 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2021-09-30 · accession 0001683168-21-006349 (CashAndCashEquivalentsAtCarryingValue)
  11. 10-K · period ending 2022-09-30 · accession 0001683168-25-000327 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
  12. 10-K · period ending 2023-09-30 · accession 0001683168-26-000203 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)